Table 2 Relationship between SWE values and histologic biomarkers of breast cancers
| Â | Eaverage | *p value | Eratio | *p value |
|---|---|---|---|---|
Lymph node | ||||
 negative (n = 46) | 108.1 (104.4 ± 31.6) | 0.695 | 12.8 (12.8 ± 6.4) | 0.027 |
 positive (n = 36) | 115.1 (106.8 ± 29.7) |  | 16.2 (17.3 ± 10.1) |  |
ER | ||||
 negative (n = 23) | 126.3 (118.5 ± 29.1) | 0.006 | 15.9 (17.6 ± 11.2) | 0.122 |
 positive (n = 59) | 109.0 (100.4 ± 29.9) |  | 13.0 (13.7 ± 6.9) |  |
PR | ||||
 negative (n = 26) | 124.8 (117.7 ± 27.9) | 0.009 | 16.2 (17.6 ± 11.3) | 0.134 |
 positive (n = 56) | 108.1 (99.8 ± 30.4) |  | 13.1 (13.5 ± 6.5) |  |
HER2 | ||||
 negative (n = 66) | 111.6 (103.4 ± 31.7) | 0.256 | 13.0 (13.6 ± 6.3) | 0.085 |
 positive (n = 16) | 119.7 (114.1 ± 24.6) |  | 15.6 (19.7 ± 13.5) |  |
Ki67 | ||||
 negative (n = 41) | 102.9 (95.0 ± 32.8) | 0.002 | 12.8 (12.6 ± 5.8) | 0.048 |
 positive (n = 41) | 119.2 (116.0 ± 24.5) |  | 14.7 (17.0 ± 10.0) |  |
Tumor grade | ||||
 1 or 2 (n = 54) | 104.4 (98.2 ± 30.9) | 0.002 | 12.4 (13.3 ± 8.8) | 0.003 |
 3 (n = 28) | 120.9 (119.5 ± 25.2) |  | 17.2 (17.6 ± 7.0) |  |
Molecular subtype | ||||
 luminal A cancer (n = 26) | 94.8 (91.4 ± 30.7) | 0.009 | 12.4 (12.1 ± 5.5) | 0.094 |
 luminal B cancer (n = 35) | 115.3 (108.2 ± 27.1) |  | 14.2 (15.1 ± 7.5) |  |
 HER2-overexpressing cancer (n = 8) | 127.6 (118.0 ± 32.1) |  | 22.4 (24.1 ± 16.5) |  |
 triple-negative cancer (n = 13) | 123.2 (118.5 ± 30.8) |  | 13.2 (13.7 ± 4.9) |  |